Literature DB >> 10449182

Qualitative and quantitative assessment of relative agonist efficacy.

A Christopoulos1, E E El-Fakahany.   

Abstract

Historically, the ability of a ligand to bind to its receptor and the ability to subsequently activate that receptor have been described as the properties of affinity and intrinsic efficacy, respectively. These properties were originally believed to be independent of one another; both are possessed by ligands classed as "agonists," and they have served as the quantitative foundation of the drug and receptor classification process. Although affinity has been interpreted readily in physicochemical terms, equivalent molecular models for efficacy remain elusive. In recent times, there has been a significant paradigm shift in our understanding of the interrelationship between affinity and intrinsic efficacy, particularly on theoretical grounds, yet the actual methods available to measure these parameters remain largely operational. Nevertheless, a number of approaches, based on both functional measurements and radioligand binding studies, are available to quantify agonist efficacy on a relative scale and, to date, these remain the most practical. This commentary discusses the most common of these methods, their advantages and limitations, the dependence of the expression of agonism on the chosen assay system, and the impact of recent biochemical and molecular biological advances on the study of efficacy. Additionally, some of the more contemporary theories regarding the molecular nature of efficacy are briefly discussed, as well as the caveats that always must be borne in mind when any determinations of relative agonist efficacy are made.

Mesh:

Substances:

Year:  1999        PMID: 10449182     DOI: 10.1016/s0006-2952(99)00087-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

Review 2.  Superagonism at G protein-coupled receptors and beyond.

Authors:  R Schrage; A De Min; K Hochheiser; E Kostenis; K Mohr
Journal:  Br J Pharmacol       Date:  2015-10-24       Impact factor: 8.739

Review 3.  Mu-opioid receptor desensitization: is morphine different?

Authors:  Mark Connor; Peregrine B Osborne; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

Review 4.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 5.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

6.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

7.  Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Authors:  Katie Leach; Richard E Loiacono; Christian C Felder; David L McKinzie; Adrian Mogg; David B Shaw; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropsychopharmacology       Date:  2009-11-25       Impact factor: 7.853

8.  A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.

Authors:  Celine Valant; Karen J Gregory; Nathan E Hall; Peter J Scammells; Michael J Lew; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

9.  Measurement of smooth muscle function in the isolated tissue bath-applications to pharmacology research.

Authors:  Brian Jespersen; Nathan R Tykocki; Stephanie W Watts; Peter J Cobbett
Journal:  J Vis Exp       Date:  2015-01-19       Impact factor: 1.355

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.